Last reviewed · How we verify

Akovaz (EPHEDRINE)

Nexus · FDA-approved withdrawn Small molecule Quality 52/100

Akovaz works by releasing norepinephrine, a natural chemical in the body that helps to relieve symptoms of respiratory and allergic conditions.

At a glance

Generic nameEPHEDRINE
SponsorNexus
Drug classNorepinephrine Releasing Agent
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval2016

Mechanism of action

Ephedrine sulfate is sympathomimetic amine that directly acts as an agonist at and ss-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic stimulation is caused by norepinephrine release from sympathetic nerves.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: